Trial record 1 of 1 for:    NCT02727387
Previous Study | Return to List | Next Study

Protocol for the Treatment of Metastatic Ewing Sarcoma (EW-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02727387
Recruitment Status : Recruiting
First Posted : April 4, 2016
Last Update Posted : April 11, 2018
Information provided by (Responsible Party):
Italian Sarcoma Group

Brief Summary:
Study for the treatment of metastatic Ewing sarcoma with high doses chemotherapy, radiotherapy and maintenance therapy.

Condition or disease Intervention/treatment Phase
Ewing's Sarcoma (ES) Drug: TEMIRI Drug: ADM Drug: IFO Drug: CYC Drug: ETO Drug: BUMEL Drug: VIN Phase 2

Detailed Description:

Study for the treatment of Ewing metastatic sarcoma with and induction phase with Vincristine (VIN), Adriamycin (ADM), Ciclofosfamide(CYC), Ifosfamide(IFO), Etoposide(ETO) and radiotherapy (RT)followed by a consolidation phase with Busulfan and Melfalan (BUMEL) and Peripheral Blood Stem Cells Transplantation (PBSCT) and a subsequent maintenance phase with Ciclofosfamide and Celecoxib for High Risk (HR) patients.

Very High Risk (VHR) patients will receive a prior frontline therapy with Temozolomide and Irinotecan (TEMIRI), while patient with lung metastasis only will undergo to total lung irradiation after PBSCT

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study With High Doses of Chemotherapy, Radiotherapy and Consolidation Therapy With Ciclofosfamide and Anticyclooxygenase 2, for the Metastatic Ewing Sarcoma
Study Start Date : May 2009
Estimated Primary Completion Date : May 2018
Estimated Study Completion Date : May 2020

Arm Intervention/treatment
2cycles of Temozolomide(500 mg/m2)+Irinotecan(250 mg/m2) and 2cycles of Vincristine(1.4mg/m2)+ Adriamycin(90mg/m2)+Ifosfamide (9gr/m2) alternes with 2 cycles of Ciclofosfamide(4g/m2)+Etoposide (600mg/m2) followed by radiotherapy (42-54 Gy) and 2cycles of Ifosfamide (9gr/m2) + Etoposide(300mg/m2) alternes with to 2cycles of Vincristine (1.4mg/m2)+ Adriamycin (80mg/m2)+ Ciclofosfamide(1.2g/m2) and Busulfan(0.8-1.2 mg/Kg)+Melfalan(140 mg/m2)+PBSCT and 6 months with Celecoxib (500mg/m2/die for<14 years old ,800 mg/die for>14 years old) Ciclofosfamide (oral therapy 35mg/m2/die for<14 years old, 50 mg/m2 for>14 years old)
Window therapy frontline for VHR patients
Other Name: Temozolomide + Irinotecan

Drug: ADM
Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Etoposide
Other Name: Adriamycin

Drug: IFO
Drug used in the Induction phase in association with Vincristine, Adriamycin, cyclophosphamide and Etoposide
Other Name: Ifosfamide

Drug: CYC
Drug used in the Induction phase in association with Vincristine, Ifosfamide, Adriamycin and Etoposide
Other Name: Cyclophosphamide

Drug: ETO
Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Adriamycin
Other Name: Etoposide

Consolidation phase
Other Name: busulfan + melphalan

Drug: VIN
Drug used in the Induction phase in association with cyclophosphamide , Ifosfamide, Adriamycin and Etoposide
Other Name: Vincristine

Primary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: Expected average 3 year ]
    Evaluation of the OS in patients treated according to the protocol

  2. Event Free Survival (DFS) [ Time Frame: Expected average 1 year ]
    Evaluation of the time in which the patient do not experience any progression, relapse of toxicity event when treated according to the protocol

Secondary Outcome Measures :
  1. Safety - Incidence and grade of treatment-emergent Adverse Events [ Time Frame: every 21 days up to 1 year ]
    Incidence and grade of treatment-emergent Adverse Events

  2. Quality of life [ Time Frame: every 3 weeks for the first 6 months and 3 monthly up to 1 year ]
    Evaluation of patient's quality of life: data will be collected by using specific oncologic Quality of Life instruments

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 40 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically proven Ewing's sarcoma
  • Age ≤ 40 years
  • No previous treatment
  • Multiple skeletal metastasis or bone marrow infiltration , with/without lung/pleural metastasis
  • Signed Informed Consent

Exclusion Criteria:

  • Localized Ewing's sarcoma
  • Any contraindications to the study treatment
  • Female patients who not accept to use an effective birth control method.
  • Pregnant or breast-feeding patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02727387

Centro di Riferimento Oncologico - Unit of Medical Oncology Not yet recruiting
Aviano, Pordenone, Italy, 33081
Contact: Maurizio Mascarin, MD    +390434659 ext 536   
Principal Investigator: Maurizio Mascarin, MD         
I.R.C.C. - Unit of Medical Oncology Recruiting
Candiolo, Torino, Italy, 10060
Contact: Massimo Aglietta, MD    +39.011.9933 ext 628   
Principal Investigator: Massimo Aglietta, MD         
Sub-Investigator: Giovanni Grignani, MD         
Istituto Ortopedico Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors Recruiting
Bologna, Italy, 40136
Contact: Stefano Ferrari, MD    +390516366199 ext 199   
Principal Investigator: Stefano Ferrari, MD         
Servizio di Oncoematologi Pediatrica Ospedale microcitemico ASL 8 Recruiting
Cagliari, Italy, Rosamaria
Contact: Rosamaria Mura, MD    +39070504208      
Principal Investigator: Rosamaria Mura, MD         
A.O. Universitaria Meyer Recruiting
Firenze, Italy, 50139
Contact: Angela Tamburini, MD    +3905556 ext 621   
Principal Investigator: Angela Tamburini, MD         
Istituto Giannina Gaslini Recruiting
Genova, Italy
Contact: Carla Manzitti, MD    0105636 2431      
Principal Investigator: Carla Manzitti, MD         
Fondazione IRCCS INT Milano Recruiting
Milano, Italy
Contact: Rossella Bertulli, MD    +390223903 ext 287   
Principal Investigator: Rossella Bertulli, MD         
Fondazione IRCCS INT Milano Recruiting
Milano, Italy
Contact: Roberto Luksch, MD    +390223903      
Principal Investigator: Roberto Luksch, MD         
Ospedale Pediatrico Bambin Gesu' Recruiting
Roma, Italy
Contact: Raffaele Cozza, MD    +39065266919      
Principal Investigator: Raffaele Cozza, MD         
Ospedale Infantile Regina Margherita - Unit of Paediatric Oncoematology Recruiting
Torino, Italy, 10126
Contact: Franca Fagioli, MD    +39.011.3135 ext 230   
Principal Investigator: Franca Fagioli, MD         
Sponsors and Collaborators
Italian Sarcoma Group

Additional Information:
Responsible Party: Italian Sarcoma Group Identifier: NCT02727387     History of Changes
Other Study ID Numbers: ISG/AIEOP EW-2
First Posted: April 4, 2016    Key Record Dates
Last Update Posted: April 11, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Sarcoma, Ewing
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Isophosphamide mustard
Etoposide phosphate
Liposomal doxorubicin
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antineoplastic Agents, Phytogenic
Topoisomerase I Inhibitors